|
| Author | Study design | Subjects | Dose used | Outcomes | Main results |
|
| McCoy et al. [2] | Multicenter, RCT. | .
Age = >6 years.
Inclusion criteria: P. aeruginosa, 3 or more courses of tobramycin in previous year, FEV1 ≥25% and ≤75% predicted | Aztreonam 75 mg for 4 weeks, BID or TID | Time to need for additional antibiotics, FEV1 | Increased time to need for additional antibiotics, improved FEV1 |
|
| Retsch-Bogart et al. [3] | Multicenter, RCT | .
Age = >13 years.
Inclusion criteria: mild and moderate lung disease, and no recent use of antibiotics, FEV1 ≥40% | Aztreonam 75 or 225 mg BID | Percent change in FEV1 at end of 14 days | No significant change in FEV1, trend of greater improvement in lung function in those with worse baseline FEV1 |
|
| Retsch-Bogart et al. [4] | Multicenter, RCT | .
Age = >6 years.
Inclusion criteria: moderate-to-severe lung disease, FEV1 ≥25% and ≤75% predicted | Aztreonam 75 mg TID for 28 days | Change in patient-reported respiratory symptom score | Significant improvement in self-reported symptom scores, improved FEV1 |
|
| Oermann et al. [5] | Open label follow-up study over 18 months | .
Age = >8 years.
Inclusion criteria: previous participant
in two other studies [2, 5] | Dose used in the main trials [2, 5] | Safety and efficacy | Improved FEV1 and symptom scores, at the end of each cycle |
|
| Wainwright et al. [6] | Multicenter, RCT | .
Age = ≥6 years.
Inclusion criteria: FEV1 >75% | Aztreonam 75 mg TID for 28 days | Change in patient-reported respiratory symptom score | No significant change in symptom score, improved FEV1 |
|
